Revelation Biosciences(US:REVB)2025-11-06 21:03Financial Performance - The company incurred a net loss of $6.4 million for the nine months ended September 30, 2025, compared to a net loss of $13.3 million for the same period in 2024[99]. - The company has incurred recurring losses since inception, with net losses expected to fluctuate significantly based on clinical study timing and expenditures[99]. - The company incurred a net loss of $6.4 million for the nine months ended September 30, 2025, with an accumulated deficit of $46.9 million[122]. - Significant operating and net losses are expected to continue as the company expands research and development activities[122]. Cash Position - As of September 30, 2025, the company had cash and cash equivalents of $12.7 million and an accumulated deficit of $46.9 million[118]. - Cash and cash equivalents available as of September 30, 2025, were $12.7 million, which is insufficient to sustain operations for one year[122]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $6.3 million, a decrease from $14.6 million in the same period of 2024[125][127]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $12.5 million, primarily from a public offering and warrant inducement[129]. - There were no net cash provided by or used in investing activities during the nine months ended September 30, 2025[128]. Expenses - Research and development expenses increased by $0.2 million, from $2.9 million for the nine months ended September 30, 2024, to $3.1 million for the same period in 2025[112]. - General and administrative expenses increased by $0.1 million, from $3.3 million for the nine months ended September 30, 2024, to $3.4 million for the same period in 2025[114]. - Total operating expenses for the nine months ended September 30, 2025, were $6.5 million, compared to $6.2 million for the same period in 2024[110]. - The company expects research and development expenses to increase substantially as it continues the development of product candidates[106]. Revenue Generation - The company has never generated revenue and does not expect to do so until product candidates successfully complete development and obtain regulatory approval[101]. - The company has never generated revenue and does not expect to do so until product candidates receive regulatory approval, which may take several years[122]. Funding and Capital - The company plans to seek additional funding through public or private equity or debt financings[98]. - The company plans to seek additional funding through public or private equity or debt financings to continue operations[123]. - The company may face dilution of existing stockholders' interests if additional capital is raised through equity offerings[121]. Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of September 30, 2025[132].